Tier 2 — strong

High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study

Hoi Nam Tse, Luca Raiteri, King Ying Wong, Kwok Sang Yee, Lai Yun Ng, Ka Yan Wai, Ching Kong Loo, Ming Houng Chan
Chest 2013 144(1):106-118

Bibliography

PubMed
PMID 23348146
DOI
10.1378/chest.12-2357
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignRandomized placebo-controlled trial
ModelHuman
Sample120 patients with stable COPD
InterventionNAC 600 mg twice daily versus placebo
Duration1 year
EndpointsSmall-airway function; Exacerbations; Quality of life; 6-minute walk distance

What the study showed, in plain terms

One-year high-dose NAC trial in stable COPD.

Key findings

Selected small-airway measures improved and exacerbations decreased, while quality of life and walking distance did not show the same pattern.

What this study can and cannot tell us

Moderate sample size and multiple endpoints; disease-specific pharmacotherapy evidence.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology